Clinical trial NCT00002228: A Study of T-20 in HIV-Positive Adults
Official title: A Phase II Evaluation of the Safety, Plasma Pharmacokinetics, and Antiviral Activity of T-20 Administered to HIV-1 Positive Adults By Continuous Subcutaneous Infusion or Subcutaneous Injection
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: HIV Infections
Keywords: Injections, Subcutaneous
HIV-1
Anti-HIV Agents
peptide T20
Lead sponsor: NIH AIDS Clinical Trials Information Service
Sponsor class: INDUSTRY
First posted: 2001-08-31
Enrollment: 78
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to see if it is safe and effective to give T-20 to HIV-positive adults. T-20 is an anti-HIV drug.

Detailed description: Patients are randomly placed into 1 of 6 groups: 4 dose levels of T-20 are given by subcutaneous infusion and 2 by subcutaneous injection. The entire study lasts 7 weeks; including a 2-week screening period, followed by 28 days of treatment and 1 week of follow-up.

Eligibility criteria: Inclusion Criteria

Concurrent Medication:

Allowed:

* Any antiretroviral agent, provided the regimen has not changed within 6 weeks of the screening visit.
* Antibiotics for bacterial infections.
* Prophylactic medications for P. carinii pneumonia and for M. avium, including azithromycin.
* Medications for symptomatic treatment such as antipyretics, analgesics, and antiemetics.

Patients must have:

HIV-1 seropositive status.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

Concurrent neoplasm (except for basal cell carcinoma of the skin, in situ carcinoma of the cervix, and non-disseminated stable Kaposi's sarcoma).

Concurrent Medication:

Excluded:

* Patients must not be taking any concurrent antiretroviral therapy (for at least 2 weeks prior to baseline) or the patient is to be on a stable antiretroviral regimen which has not changed for at least 6 weeks prior to baseline.
* Treatment with any of the following:
* immunomodulators, biological response modifiers, chemotherapy that cannot be discontinued for the duration of the study, astemizole, terfenadine, cisapride, triazolam, midazolam, rifampin, clarithromycin, or an investigational drug within 30 days prior to the initial visit.

Patients with the following prior conditions are excluded:

* Evidence of active opportunistic infections, or unexplained temperature greater than or equal to 38.5 Celsius for 7 consecutive days within 30 days prior to screening visit.
* Chronic diarrhea (defined as greater than 3 liquid stools per day which persists for 15 days) within 30 days prior to screening visit.
* Diagnosis of hemophilia or other clotting disorders.

Prior Medication:

Excluded:

- Prior treatment with an HIV vaccine.

Prior Treatment:

Excluded:

Major organ allograft.

Risk Behavior:

Excluded:

Evidence of substance abuse or addiction that, in the opinion of the investigator, may interfere with the patient's ability to comply with the dosing schedule and protocol evaluations.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: Univ of Alabama at Birmingham / 1917 AIDS O/P Cln
state: Alabama
city: Los Angeles
country: United States
facility: UCLA School of Medicine / Ctr for Research and Education
state: California
city: San Francisco
country: United States
facility: San Francisco Gen Hosp
state: California
city: San Francisco
country: United States
facility: Quest Clinical Research
state: California
city: Altamonte Springs
country: United States
facility: IDC Research Initiative
state: Florida
city: Chicago
country: United States
facility: Northwestern Univ / Infect Dis Div / Pasavant Pav 828
state: Illinois
city: Baltimore
country: United States
facility: Johns Hopkins Hosp
state: Maryland
city: Brookline
country: United States
facility: CRI of New England
state: Massachusetts
city: New York
country: United States
facility: NYU Med Ctr / C & D Building
state: New York
city: Chapel Hill
country: United States
facility: Univ North Carolina at Chapel Hill / Dept of Medicine
state: North Carolina
city: Houston
country: United States
facility: Univ of Texas / Thomas Street Clinic
state: Texas
Study officials:
name: Sam Hopkins
role: STUDY_CHAIR
References: